These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

117 related items for PubMed ID: 12404279

  • 1. Selective aromatase inhibition for patients with androgen-independent prostate carcinoma.
    Smith MR, Kaufman D, George D, Oh WK, Kazanis M, Manola J, Kantoff PW.
    Cancer; 2002 Nov 01; 95(9):1864-8. PubMed ID: 12404279
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
    Miller N, Smolkin ME, Bissonette E, Theodorescu D.
    Cancer; 2005 Jun 15; 103(12):2499-506. PubMed ID: 15852361
    [Abstract] [Full Text] [Related]

  • 5. Phase II trial of oral cyclophosphamide, prednisone, and diethylstilbestrol for androgen-independent prostate carcinoma.
    Hellerstedt B, Pienta KJ, Redman BG, Esper P, Dunn R, Fardig J, Olson K, Smith DC.
    Cancer; 2003 Oct 15; 98(8):1603-10. PubMed ID: 14534875
    [Abstract] [Full Text] [Related]

  • 6. A phase II trial of green tea in the treatment of patients with androgen independent metastatic prostate carcinoma.
    Jatoi A, Ellison N, Burch PA, Sloan JA, Dakhil SR, Novotny P, Tan W, Fitch TR, Rowland KM, Young CY, Flynn PJ.
    Cancer; 2003 Mar 15; 97(6):1442-6. PubMed ID: 12627508
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Letrozole normalizes serum testosterone in severely obese men with hypogonadotropic hypogonadism.
    de Boer H, Verschoor L, Ruinemans-Koerts J, Jansen M.
    Diabetes Obes Metab; 2005 May 15; 7(3):211-5. PubMed ID: 15811136
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Prostate-specific antigen doubling time predicts response to deferred antiandrogen therapy in men with androgen-independent prostate cancer.
    Shulman MJ, Karam JA, Benaim EA.
    Urology; 2004 Apr 15; 63(4):732-6. PubMed ID: 15072890
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Determining dosing intervals for luteinizing hormone releasing hormone agonists based on serum testosterone levels: a prospective study.
    Pathak AS, Pacificar JS, Shapiro CE, Williams SG.
    J Urol; 2007 Jun 15; 177(6):2132-5; discussion 2135. PubMed ID: 17509298
    [Abstract] [Full Text] [Related]

  • 17. Phase II study of low dose and high dose conjugated estrogen for androgen independent prostate cancer.
    Pomerantz M, Manola J, Taplin ME, Bubley G, Inman M, Lowell J, Beard C, Kantoff PW, Oh WK.
    J Urol; 2007 Jun 15; 177(6):2146-50. PubMed ID: 17509304
    [Abstract] [Full Text] [Related]

  • 18. Clinical features of patients who present with metastatic prostate carcinoma and serum prostate-specific antigen (PSA) levels < 10 ng/mL: the "PSA negative" patients.
    Birtle AJ, Freeman A, Masters JR, Payne HA, Harland SJ, BAUS Section of Oncology Cancer Registry.
    Cancer; 2003 Dec 01; 98(11):2362-7. PubMed ID: 14635070
    [Abstract] [Full Text] [Related]

  • 19. Phase II study of imatinib mesylate in patients with prostate cancer with evidence of biochemical relapse after definitive radical retropubic prostatectomy or radiotherapy.
    Bajaj GK, Zhang Z, Garrett-Mayer E, Drew R, Sinibaldi V, Pili R, Denmeade SR, Carducci MA, Eisenberger MA, DeWeese TL.
    Urology; 2007 Mar 01; 69(3):526-31. PubMed ID: 17382158
    [Abstract] [Full Text] [Related]

  • 20. Prospective randomized Phase II trial of pegylated doxorubicin in the management of symptomatic hormone-refractory prostate carcinoma.
    Heidenreich A, Sommer F, Ohlmann CH, Schrader AJ, Olbert P, Goecke J, Engelmann UH.
    Cancer; 2004 Sep 01; 101(5):948-56. PubMed ID: 15329902
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.